Subjective Cognitive Decline (SCD)NCT07463391
Chinese Classics Recitation Training in Subjective Cognitive Decline
A study testing Memory training by Chinese Classics recitation in people with Subjective Cognitive Decline (SCD) and Subjective Cognitive Decline, run by China Medical University Hospital at 1 site in Taiwan.
Trial summary
Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Subjective Cognitive Decline (SCD), Subjective Cognitive Decline
- What is being tested?
- Memory training by Chinese Classics recitation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Aug 2026to 31 Dec 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 60 years old
- At least two "yes" responses to the following questions are required:
- Forgetting where things are placed?
- Unable to recall the names of good friends?
- Unable to follow and recall conversation?
- Subjective memory problems?
- Consider own memory to be worse than others of a similar age?
Who cannot join
- Objective cognitive impairment defined as ≥ 1.5 standard deviations below standardized cognitive testing (e.g., MMSE)
- Diagnosis of MCI
- Clinical Dementia Rating (CDR) ≥ 0.5
- Diagnosis of major depressive disorder
- Beck Anxiety Inventory score ≥ 16
- Other medical or neurological conditions that could explain cognitive decline (e.g., vascular dementia, traumatic brain injury)
- Claustrophobia
- Contraindications of MRI (e.g., non-MRI-compatible cardiac pacemaker or devices implanted within the past three months)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
China Medical University Hospital
Taichung, 404
Sheng-Ta Tsai, M.D., Ph.D., 886-928262460, 027056@tool.caaumed.org.tw
Sheng-Ta Tsai, M.D., Ph.D.
About this study
Official title: The Effect of Memory Training by Chinese Classics Recitation on Individuals With Subjective Cognitive Decline
Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in culturally specific educational contexts.
This randomized, assessor-blinded, controlled clinical trial will enroll 60 individuals with SCD to evaluate the effects of a six-month structured Chinese Classics recitation training program. Participants will be randomly assigned to either an intervention group or a non-active control group. Assessments will be conducted at baseline, immediately post-intervention, and during annual follow-up.
Multimodal evaluations will include neuropsychological testing, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), blood biomarker profiling, gut microbiota analysis, and fecal metabolomics. The study aims to examine clinical outcomes and explore potential neurobiological and systemic correlates associated with culturally adapted cognitive training.
- Being tested
- Memory training by Chinese Classics recitation
- Keywords
- subjective cognitive decline, memory training, Chinese Classics, recitation, randomized controlled trial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Memory training by Chinese Classics recitationBehavioural
At least five minutes memory training per day, for six months
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Chinese Classics Recitation for six months Receives: Behavioral: Memory training by Chinese Classics recitation |
| non-active control | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in task-related brain activation measured by functional MRI
Unit of measure:
Whole-brain blood-oxygen-level-dependent (BOLD) signal change (%)
Detail Functional magnetic resonance imaging (fMRI) will be used to evaluate changes in task-related brain activation associated with the intervention. Whole-brain blood-oxygen-level-dependent (BOLD) signals will be analyzed using voxel-wise general linear modeling to identify activation patterns during task performance compared with resting baseline. First-level analyses will generate subject-specific contrast maps reflecting task-related neural activation. Group-level random-effects analyses will then be conducted to compare activation patterns between study groups and across time points. Statistical significance will be determined using a voxel-level threshold corrected for multiple comparisons using the false discovery rate (FDR). Effect sizes extracted from significant brain regions will be used for group-level comparisons.
Measured: Baseline and 6 months
Secondary outcomes (17)
Resting-state electroencephalogram (EEG) spectral activity
Unit of Measure µV²/Hz (power spectral density)
Detail Resting electroencephalogram (EEG) recordings will be acquired using a standard 21-electrode montage positioned according to the International 10-20 system. Electrode impedance will be maintained below 10 kΩ, with a minimum sampling rate of 256 Hz. Recordings will be performed in a quiet, dimly lit environment with participants seated comfortably and instructed to remain awake with their eyes closed.
EEG preprocessing and analysis will be conducted using MNE-Python implemented in Python. The preprocessing pipeline will include re-referencing, resampling to 250 Hz, and band-pass filtering between 0.1 and 41 Hz. Artifact-free EEG signals will be segmented into non-overlapping 2-second epochs for subsequent spectral analysis. Quantitative EEG measures will be derived from the processed signals to characterize resting-state brain activity.
Measured: Baseline and 6 months
Global Cognitive Function - MMSE
Outcome Measure Total score on the Mini-Mental State Examination (MMSE)
Unit of Measure points
Detail The MMSE is a widely used cognitive screening instrument assessing orientation, attention, memory, language, and visuospatial ability. Total score ranges from 0-30, with higher scores indicating better cognitive function.
Measured: Baseline and 6 months
Global Cognitive Function - MoCA
Outcome Measure Total score on the Montreal Cognitive Assessment (MoCA)
Unit of Measure points
Detail The MoCA evaluates multiple cognitive domains including executive function, memory, attention, language, abstraction, and orientation. Total score ranges from 0-30, with higher scores indicating better cognitive performance.
Measured: Baseline and 6 months
Verbal Episodic Memory - RAVLT
Outcome Measure Total recall score on the Rey Auditory Verbal Learning Test (RAVLT)
Unit of Measure points
Detail The RAVLT assesses verbal learning and episodic memory through repeated recall of word lists across trials. Total recall score reflects the number of correctly recalled words, with higher scores indicating better memory performance.
Measured: Baseline and 6 months
Executive Function - Stroop Test
Outcome Measure Interference completion time on the Stroop Color and Word Test
Unit of Measure seconds
Detail The Stroop test measures selective attention and cognitive control. The interference condition requires participants to name the ink color of incongruent color words. Lower completion time indicates better executive function.
Measured: Baseline and 6 months
Working Memory - Digit Span
Outcome Measure Total span score on the Digit Span Test
Unit of Measure points
Detail Digit Span evaluates auditory attention and working memory through forward and backward recall of number sequences. Higher scores indicate better working memory capacity.
Measured: Baseline and 6 months
Language Function - Boston Naming Test
Outcome Measure Total score on the Short Form (15 items) of the Boston Naming Test
Unit of Measure points
Detail The Boston Naming Test assesses confrontational naming ability. The short form contains 15 items, with total score ranging from 0-15, and higher scores indicating better language function.
Measured: Baseline and 6 months
Dementia Severity - CDR
Outcome Measure Global score on the Clinical Dementia Rating (CDR)
Unit of Measure scale score
Detail The CDR is a clinician-rated scale evaluating cognitive and functional performance in dementia. Global score ranges from 0 (no impairment) to 3 (severe dementia).
Measured: Baseline and 6 months
Vascular Cognitive Risk - Hachinski Score
Outcome Measure Total score on the Hachinski Ischemic Score
Unit of Measure points
Detail The Hachinski Ischemic Score differentiates vascular from degenerative causes of cognitive impairment. Scores range from 0-18, with higher scores suggesting greater vascular contribution.
Measured: Baseline
Depressive Symptoms - GDS
Outcome Measure Total score on the Geriatric Depression Scale (GDS)
Unit of Measure points
Detail The GDS evaluates depressive symptoms in older adults. Higher scores indicate more severe depressive symptoms.
Measured: Baseline and 6 months
Anxiety Symptoms - BAI
Outcome Measure Total score on the Beck Anxiety Inventory (BAI)
Unit of Measure points
Detail The BAI measures the severity of anxiety symptoms. Total score ranges from 0-63, with higher scores indicating greater anxiety.
Measured: Baseline and 6 months
Cognitive Reserve - CRI-q
Outcome Measure Cognitive reserve index score on the Cognitive Reserve Index questionnaire
Unit of Measure index score
Detail The CRI-q quantifies lifetime cognitive reserve based on education, occupational complexity, and leisure activities. Higher index scores indicate greater cognitive reserve.
Measured: Baseline
APOE genotype distribution
Unit of Measure genotype category
Detail Genomic DNA will be extracted from peripheral blood samples to determine the genotype of the APOE, a major genetic risk factor associated with cognitive decline and Alzheimer's disease. Participants will be categorized according to APOE genotype (e.g., ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4, ε4/ε4).
Measured: Baseline
Circulating inflammatory and stress biomarkers (IL-6, TNF-α, hsCRP, and cortisol)
Unit of Measure IL-6: pg/mL TNF-α: pg/mL hsCRP: mg/dL Cortisol: µg/dL
Detail Peripheral venous blood samples will be collected after overnight fasting to quantify circulating inflammatory and stress-related biomarkers, including Interleukin-6, Tumor necrosis factor alpha, High-sensitivity C-reactive protein, and Cortisol. Blood samples will be collected in EDTA anticoagulant tubes and processed within 30 minutes by centrifugation at 2,000 × g for 10 minutes at 4 °C. Plasma will be aliquoted and stored at -80 °C until analysis.
Cytokine concentration HsCRP concentrations will be measured using high-sensitivity immunoassays to evaluate systemic low-grade inflammation. Plasma cortisol levels will be measured using validated immunoassay methods to assess hypothalamic-pituitary-adrenal (HPA) axis activity and physiological stress responses. Changes in these biomarkers will be analyzed to explore potential inflammatory and neuroendocrine mechanisms associated with the intervention.
Measured: Baseline and 6 months
Gut microbiota diversity (Shannon index)
Unit of Measure Shannon diversity index
Detail Fecal samples will be collected to evaluate changes in gut microbial diversity associated with the intervention. Microbial community composition will be characterized using full-length 16S rRNA gene sequencing, enabling species-level taxonomic identification of intestinal microorganisms. Alpha diversity will be quantified using the Shannon diversity index, which reflects both species richness and evenness within the microbial community. Changes in Shannon diversity between baseline and follow-up will be analyzed to assess intervention-related alterations in gut microbiota diversity.
Measured: Baseline and 6 months
Gut microbiota taxonomic composition
Unit of Measure Relative abundance (%)
Detail Fecal microbiota composition will be analyzed using full-length 16S rRNA gene sequencing to determine the relative abundance of bacterial taxa at different taxonomic levels (e.g., phylum, genus, and species). Differential abundance analyses will be conducted to identify microbial taxa whose relative abundance changes over time or differs between study groups.
Measured: Baseline and 6 months
Fecal metabolomic profiles related to the gut-brain axis
Unit of Measure Metabolite concentrations (µmol/g feces or relative abundance)
Detail Fecal metabolomic profiling will be performed using Liquid chromatography-tandem mass spectrometry to quantify metabolites associated with gut microbiota-host interactions. Metabolites of interest include short-chain fatty acids, bile acids, tryptophan pathway metabolites, neurotransmitter precursors, and inflammation-related metabolites. These analyses will be used to investigate potential metabolic pathways linking gut microbial activity with cognitive and neurophysiological outcomes.
Measured: Baseline and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2026
- Study start1 Aug 2026
- Primary completion31 Jul 2029 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Subjective Cognitive Decline (SCD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- China Medical University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sheng-Ta Tsai, China Medical University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07463391
- Sponsor's protocol ID
- CMUH115-REC2-001
- Status last verified
- Mar 2026
- First submitted
- 1 Mar 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data will be made available upon reasonable request after publication.
Publications
Su TS, Su KP, Hsueh PR, Lai ZL, Chen CM, Lai YC, Chen CS, Nian X, Chang YW, Tsai ST. Memory training through Chinese classics recitation for individuals with subjective cognitive decline: study protocol for a pilot study. Front Aging Neurosci. 2026 Jul 20;18:1830299. doi: 10.3389/fnagi.2026.1830299. eCollection 2026.
PubMed 42548715
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Memory Training by Chinese Classics Recitation on Individuals With Subjective Cognitive Decline
- ClinicalTrials.gov ID
- NCT07463391
- Acronym / sponsor ID
- CMUH115-REC2-001
- Keywords
- subjective cognitive decline, memory training, Chinese Classics, recitation, randomized controlled trial
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- China Medical University HospitalUniversity, hospital or other
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 31 Jul 2029 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 11 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in culturally specific educational contexts.
This randomized, assessor-blinded, controlled clinical trial will enroll 60 individuals with SCD to evaluate the effects of a six-month structured Chinese Classics recitation training program. Participants will be randomly assigned to either an intervention group or a non-active control group. Assessments will be conducted at baseline, immediately post-intervention, and during annual follow-up.
Multimodal evaluations will include neuropsychological testing, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), blood biomarker profiling, gut microbiota analysis, and fecal metabolomics. The study aims to examine clinical outcomes and explore potential neurobiological and systemic correlates associated with culturally adapted cognitive training.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Memory training by Chinese Classics recitationChinese Classics Recitation for six months |
| non-active control | No intervention | – |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥ 60 years old
- At least two "yes" responses to the following questions are required:
Key exclusion criteria (8 listed)
- Objective cognitive impairment defined as ≥ 1.5 standard deviations below standardized cognitive testing (e.g., MMSE)
- Diagnosis of MCI
- Clinical Dementia Rating (CDR) ≥ 0.5
- Diagnosis of major depressive disorder
- Beck Anxiety Inventory score ≥ 16
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Memory training by Chinese Classics recitationAt least five minutes memory training per day, for six months | Behavioural | Intervention |
Primary outcome
Change in task-related brain activation measured by functional MRI
Time frame: Baseline and 6 months
Unit of measure: Whole-brain blood-oxygen-level-dependent (BOLD) signal change (%) Detail Functional magnetic resonance imaging (fMRI) will be used to evaluate changes in task-related brain activation associated with the intervention. Whole-brain blood-oxygen-level-dependent (BOLD) signals will be analyzed using voxel-wise general linear modeling to identify activation patterns during task performance compared with resting baseline. First-level analyses will generate subject-specific contrast maps reflecting task-related neural activation. Group-level random-effects analyses will then be conducted to compare activation patterns between study groups and across time points. Statistical significance will be determined using a voxel-level threshold corrected for multiple comparisons using the false discovery rate (FDR). Effect sizes extracted from significant brain regions will be used for group-level comparisons.
17 secondary outcomes
Resting-state electroencephalogram (EEG) spectral activity
Time frame: Baseline and 6 months
Global Cognitive Function - MMSE
Time frame: Baseline and 6 months
Global Cognitive Function - MoCA
Time frame: Baseline and 6 months
Verbal Episodic Memory - RAVLT
Time frame: Baseline and 6 months
Executive Function - Stroop Test
Time frame: Baseline and 6 months
Working Memory - Digit Span
Time frame: Baseline and 6 months
Language Function - Boston Naming Test
Time frame: Baseline and 6 months
Dementia Severity - CDR
Time frame: Baseline and 6 months
Vascular Cognitive Risk - Hachinski Score
Time frame: Baseline
Depressive Symptoms - GDS
Time frame: Baseline and 6 months
Anxiety Symptoms - BAI
Time frame: Baseline and 6 months
Cognitive Reserve - CRI-q
Time frame: Baseline
APOE genotype distribution
Time frame: Baseline
Circulating inflammatory and stress biomarkers (IL-6, TNF-α, hsCRP, and cortisol)
Time frame: Baseline and 6 months
Gut microbiota diversity (Shannon index)
Time frame: Baseline and 6 months
Gut microbiota taxonomic composition
Time frame: Baseline and 6 months
Fecal metabolomic profiles related to the gut-brain axis
Time frame: Baseline and 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Results publication: PubMed 42548715Su TS, Su KP, Hsueh PR, Lai ZL, Chen CM, Lai YC, Chen CS, Nian X, Chang YW, Tsai ST. Memory training through Chinese classics recitation for individuals with subjective cognitive decline: study protocol for a pilot study. Front Aging Neurosci. 2026 Jul 20;18:1830299. doi: 10.3389/fnagi.2026.1830299. eCollection 2026.
- Published study protocolLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual participant data will be made available upon reasonable request after publication.
Related trials for Subjective Cognitive Decline (SCD)
Recruiting
The Efficacy of an IADL-based Non-immersive Virtual Reality Training Program to Enhance ADL Performance and Cognitive Function for Persons at Risk of Dementia
Cognitive Enhancement, Subjective Cognitive Decline (SCD)
RecruitingObservational study
Fuzhou Aging Brain Health Initiative
Dementia, Alzheimer Dementia (AD)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Enrolling by invitationObservational study
Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog
Mild Cognitive Impairment, Subjective Cognitive Decline
RecruitingPhase 2
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Memory training by Chinese Classics recitation in people with Subjective Cognitive Decline (SCD) and Subjective Cognitive Decline, run by China Medical University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sheng-Ta Tsai, M.D., Ph.D. (886-928262460, tshengdar@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in task-related brain activation measured by functional MRI (time frame: Baseline and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07463391, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.